Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05987709 · ClinicalTrials.gov registry record · NA
Study of Colorectal Cancer Screening Options
A NA study of Colon Cancer, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 2,004
- Enrollment target
- 1
- Study location
NCT05987709: Completed NA study of Colon Cancer, sponsored by Kaiser Permanente.
NCT05987709 is a NA study of Colon Cancer that has completed, run by Kaiser Permanente. The registered enrollment target is 2,004 participants, below the 4,436-participant average among 97 other Colon Cancer trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05987709, a NA study of Colon Cancer, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,004 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.
Primary Outcome
Assess the percentage who received any CRC screening test (blood draw, FIT or FIT-DNA, or flexible sigmoidoscopy or colonoscopy) within 3 months of eligibility determination among eligible individuals in the blood test and usual care groups.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST GuardantSHIELD Blood Test
Study Locations (1)
Oregon
- Kaiser Permanente Northwest - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,004 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2023-06-15 |
| Phase | NA |
What the finished NCT05987709 record still lists
NCT05987709 is an interventional study that assigns participants to a tested intervention. Its 2,004 participants enrollment target places it among the larger protocols in the corpus, below the 4,436-participant average among 97 other Colon Cancer trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which GuardantSHIELD Blood Test is the first listed.
NCT05987709 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05987709 about?
NCT05987709 is a clinical study titled "Study of Colorectal Cancer Screening Options". The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.
What is the current status of trial NCT05987709?
This trial is currently completed. It is a NA study. The enrollment target is 2,004 participants. The study started on 2022-03-17. Estimated completion is 2023-06-15.
What conditions does trial NCT05987709 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT05987709?
The interventions under investigation include: GuardantSHIELD Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05987709?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05987709 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05987709's enrollment target sits among peer trials
2,004 7th of 97 higher than 91 of 97 other Colon Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Resilience and Equity in Aging, Cancer, and Health (REACH)
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
PrehabPal: A Digital Tool to Help Older Adults Prepare for Cancer Surgery
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI